Early ibrutinib shows promise for High-Risk CLL patients before symptoms appear
NCT ID NCT03207555
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This study looked at whether giving the drug ibrutinib early to people with chronic lymphocytic leukemia (CLL) who have high-risk features but no symptoms is better than waiting until symptoms develop. It involved 23 participants and measured how many achieved complete or partial remission after 24 months. The goal was to see if early treatment can control the disease better than the standard watch-and-wait approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS STATED AS PRIMARY LYMPHOID HAEMATOPOIETIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.